Powder: -20°C for 3 years
In solvent: -80°C for 2 years
<a href="/target/PD_1_PD_L1" style="display: inline; color: #c13a36">PD-1/PD-L1</a>-IN-9 is a potent and orally active inhibitor of <a href="/target/PD_1_PD_L1" style="display: inline; color: #c13a36">PD-1/PD-L1</a> interaction, IC50 = 3.8 nM. <a href="/target/PD_1_PD_L1" style="display: inline; color: #c13a36">PD-1/PD-L1</a>-IN-9 can enhance the killing activity of tumor cells by immune cells. <a href="/target/PD_1_PD_L1" style="display: inline; color: #c13a36">PD-1/PD-L1</a>-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 159.00 | |
2 mg | In stock | $ 238.00 | |
5 mg | In stock | $ 317.00 | |
10 mg | In stock | $ 527.00 | |
25 mg | In stock | $ 995.00 | |
50 mg | In stock | $ 1,535.00 | |
100 mg | In stock | $ 2,255.00 |
Description | PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, IC50 = 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model. |
In vitro | PD-1/PD-L1-IN-9 (46.9-1500 nM; pretreated for 2 h) dose-dependently significantly activates the antitumor immunity of PBMCs to MDB-MB 231 cells, EC50 = ∼100 nM[1]. |
In vivo | PD-1/PD-L1-IN-9 (40-80 mg/kg; p.o. once a day for 2 weeks) inhibits tumor growth in a dose-dependent manner and does not cause any body weight loss or mortality of mice. PD-1/PD-L1-IN-9 (3 mg/kg; a single i.v.) exhibits half-life (t1/2=4.2 h), plasma clearance (Cl=11.5 L/h/kg) and Cmax (1233 ng/mL) in rats. PD-1/PD-L1-IN-9 (25 mg/kg; a single p.o.) exhibits moderate oral bioavailability (F=22 %), half-life (t1/2=6.4 h) and Cmax (192 ng/mL) in rats[1]. |
Molecular Weight | 348.446 |
Formula | C22H24N2O2 |
CAS No. | 2628506-54-5 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 90 mg/mL (258.3 mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PD-1/PD-L1-IN-9 2628506-54-5 Apoptosis Cell Cycle/Checkpoint Immunology/Inflammation PD-1/PD-L1 PD1/PDL1IN9 PD 1/PD L1 IN 9 Inhibitor inhibitor inhibit